

Summary of the Proposed Combination

*[In terms of Regulation 13 (1B) of the Competition Commission of India
(Procedure in regard to the transaction of business relating to
combinations), 2011, as amended on 7 January 2016]*

A. Name of the parties to the Proposed Combination

1. LG Chem, Ltd. (“**LG Chem**”), and LG Life Sciences Ltd. (“**LG LS**”).

B. Type of the Proposed Combination

2. The proposed transaction was announced on 12 September 2016 by LG Chem and LG LS, on which date the board of directors of LG Chem and LG LS, respectively, approved the merger of LG LS with and into LG Chem. On completion of the proposed transaction, LG Chem will be the surviving company, whereas LG LS would be the dissolved company (“**Proposed Combination**”).

C. Area of the activity of the Parties to the Proposed Combination

LG Chem

3. LG Chem is a company incorporated in the Republic of Korea. LG Chem is part of the LG Corporation. LG Chem is a company

engaged in the business of manufacture of chemicals. The businesses of LG Chem is organized as follows: (a) Basic Materials & Chemicals Division; (b) Energy Solutions Division; (c) IT & Electronic Materials Division; and (d) Advanced Materials Division. LG Chem is present in India through 3 subsidiaries i.e., LG Chemicals India Private Limited, LG Polymers India Private Limited and LGC Petrochemical India Private Limited.

LG LS

4. LG LS is a company incorporated in the Republic of Korea. LG LS is part of the LG Corporation. The primary business areas of LG LS are pharmaceutical products (including animal health business) and specialty chemicals. LG LS is present in India through 1 subsidiary i.e., LG LS India Private Limited.

D. Relevant market(s) to which the Proposed Combination relates

5. There is no horizontal overlap between LG Chem (including its Indian entities) and LG LS in India (including LG LS India). Further, as mentioned above, there is no vertical relationships between LG Chem (including its Indian entities) and LG LS (and LG LS India). It is the Parties' submission that the definition for the relevant product market can be left open as there are no overlaps between the Parties.

6. For the Hon'ble Commissions ease of assessment:
- In relation to the pharmaceutical products sold by LG LS, the relevant product market may be defined based on the therapeutic areas of the LG LS products sold in India (i.e., treatment for Infertility, Anemia (EPO), Growth hormone deficiency, Treating knee joints, Dermal filler , Intraocular use, Endometriosis, Immunosuppressant, Anti-bacterial, Osteoporosis, Management of Hypocalcemia during CKD, Delayed Dialysis, Prevention of Hyperphosphatemia, Erythropoeisis Stimulating Agent, Prevention of premature ovulation).
 - In relation to the agro-chemical products sold by LG LS, the relevant product market may be defined as the 'market for herbicides in India'
7. The relevant geographic market is the entire territory of the country of India.